Search

Your search keyword '"Erica, Curti"' showing total 33 results

Search Constraints

Start Over You searched for: Author "Erica, Curti" Remove constraint Author: "Erica, Curti"
33 results on '"Erica, Curti"'

Search Results

1. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

2. Neuromyelitis Optica Spectrum Disorder Attack Triggered by Herpes Zoster Infection

3. The effect of air pollution on COVID‐19 severity in a sample of patients with multiple sclerosis

4. Herpes zoster preceding neuromyelitis optica spectrum disorder: casual or causal relationship? A systematic literature review

5. The impact of PM2.5, PM10 and NO2 on Covid-19 severity in a sample of patients with multiple sclerosis: A case-control study

6. Secondary cluster headache due to a contralateral demyelinating periaqueductal gray matter lesion

7. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis

8. Location of first attack predicts the site of subsequent relapses in multiple sclerosis

9. The importance of communication in the diagnosis of multiple sclerosis

10. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis

11. The real-world effectiveness of natalizumab and fingolimod in relapsing-remitting multiple sclerosis. An Italian multicentre study

12. Dimethyl fumarate-induced lymphocyte count drop is related to clinical effectiveness in relapsing-remitting multiple sclerosis

13. SARS-CoV-2 serology after COVID-19 in multiple sclerosis: An international cohort study

14. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context

15. Exit Strategies in Natalizumab-Treated RRMS at High Risk of Progressive Multifocal Leukoencephalopathy: a Multicentre Comparison Study

16. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis

17. Switch from sequestering to anti-CD20 depleting treatment: disease activity outcomes during wash-out and in the first 6 months of ocrelizumab therapy

18. The contribution of enhancing lesions in monitoring multiple sclerosis treatment: is gadolinium always necessary?

19. Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

20. Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?

21. Successful intravenous immunoglobulin treatment in relapsing MOG-antibody-associated disease

23. Late Breaking News Abstracts

24. Definitive childlessness in women with multiple sclerosis: a multicenter study

25. Efficacy of different rituximab therapeutic strategies in patients with neuromyelitis optica spectrum disorders

26. MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study

27. Five- and seven-year prognostic value of new effectiveness measures (NEDA, MEDA and six-month delayed NEDA) in relapsing-remitting multiple sclerosis

29. Italian Alemtuzumab Study Group. No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world study

30. First-line disease-modifying drugs in relapsing-remitting multiple sclerosis: an Italian real-life multicenter study on persistence

32. Correlation between cortical lesions and cognitive impairment in multiple sclerosis

33. Signs and symptoms of COVID-19 in patients with multiple sclerosis

Catalog

Books, media, physical & digital resources